Introduction
============

Primary liver cancer is one of the most common malignant tumors in the world, among which hepatocellular carcinoma (HCC) accounts for approximately 70--85% ([@b1-ol-0-0-7792]). Surgical operation, local ablation, radiotherapy and chemotherapy provide opportunities to cure or prolong the survival time of patients. However, the 5-year recurrence rate after primary liver cancer operation is as high as 45--60%, seriously affecting the prognosis of patients with liver cancer ([@b2-ol-0-0-7792]--[@b4-ol-0-0-7792]). Therefore, searching for the indexes for evaluating the poor prognosis of HCC, such as proliferative activity and early recurrence, is of significance for the tumor staging, selection of treatment plan and prognosis.

Ki-67 is a kind of nuclear antibody Ki-67 protein, mainly existing in the dense fibrillar components of nucleoli and cortices, which is a reliable index of detecting the tumor cell proliferative activity ([@b5-ol-0-0-7792]). The biological manifestations of tumor are closely related to its proliferative activity. The higher the expression of Ki-67 is, the faster the tumor cell proliferation will be and the higher the probability of metastasis will also be ([@b6-ol-0-0-7792],[@b7-ol-0-0-7792]). However, there are few studies on the correlation between contrast-enhancement ultrasound of HCC and Ki-67 immunohistochemistry and other prognostic factors.

Compared with enhancement MRI/CT, PET and other examinations, contrast-enhancement ultrasound (CEUS) is characterized by the convenient and efficient application, wide indications and no radiation, and it can show the whole process of contrast enhancement for tumor and liver parenchyma in a real-time and dynamic manner, which not only improves the value of diagnosis and differential diagnosis, but also indirectly reflects some biological manifestations of tumors ([@b8-ol-0-0-7792]--[@b10-ol-0-0-7792]). In the field of contrast-enhancement ultrasound, there are some scholars who use special computer software to conduct the quantization parameter analysis for CEUS images of HCC, establish the peak intensity curve, and study the relationship between CEUS parameters on the curve and microvessel density (MVD), microvessel invasion (MVI) and tumor tissue differentiation degree ([@b11-ol-0-0-7792]--[@b14-ol-0-0-7792]). These factors are associated with the recurrence of liver cancer and the survival time of liver cancer patients.

This study aimed to evaluate the relationship between the enhancement mode and parameters of CEUS for HCC and the prognostic factors and clinical recurrence, and evaluate the biological behavior and prognosis of liver cancer from the perspective of ultrasonography, so as to provide new non-invasive evaluation indexes of prognosis.

Patients and methods
====================

### Subjects

One hundred and eighty patients with HCC confirmed by operation or puncture were collected, and they all had the background of liver cirrhosis. The tumor samples received immunohistochemical Ki-67 and AFP-labeled staining. This study was approved by the Ethics Committee of Qianfoshan Hospital Affiliated to Shandong University (Jinan, China). Signed written informed consents were obtained from all participants before the study.

### Pathological examination of Ki-67

Each section was observed via 10 visual fields randomly selected under high-power microscope (×400), and the percentage of brown-stained cell nuclei every 100 cells was the percentage of Ki-67. Ki-67 was divided into Ki-67-positive group (\>10%) and the Ki-67-negative group (≤10%) according to the percentage of Ki-67.

### Microvessel density, MVD

After the blood vessels in tumor tissues were stained by antigen-antibody reaction, the slide was glanced with low-power microscope (×40-×100) to find the area with the highest blood vessel density. Then the stained blood vessels within the field were counted under high-power microscope (×400). The mean MVD of the patients included was calculated, and they were divided into the high-MVD group (greater than the mean) and low-MVD group (lower than the mean).

### Microvessel invasion, MVI

Microvessel infiltration means that multiple or massed cancer cells can be found in venules in para-cancer mesenchyme, obvious endothelial cells can be found around the lumen and red blood cells may appear within the lumen. Patients were divided into the MVI-positive group (MVI was found) and MVI-negative group (no MVI was found).

### Contrast-enhancement ultrasound, CEUS

Color Doppler ultrasound was used to record the lesion site and size, internal echo and number, and Doppler blood flow signal; and then the contrast agent was injected under the radiography mode, and the timer and recording were started. The sum of two maximum orthogonal radial lines of lesion on the same section was taken as size of the tumor; according to the changes before and after CEUS, those greater than the mean of all change values were enrolled into the significant change group; otherwise, they were enrolled into the non-significant change group. The image at 10--30 sec after injection of contrast agent was taken as arterial phase. The images with peak intensity were observed; if there were low enhancement or no enhancement area in different sizes in the lesion, the enhancement mode was seen as the inhomogeneous enhancement. The irregular enhancement form of lesion was regarded as the irregular tumor form. Whether there were tortuous blood vessels in the enhancement process at arterial phase were observed. The images at 90--120 sec after injection of contrast agent were selected as the portal phase. In comparison with surrounding liver parenchyma, the extinction time of contrast agent was recorded, the enhancement intensity and regression degree of lesion at portal phase were observed.

### Recurrence of liver cancer

If the focal hepatic lesions showed the typical manifestation of HCC or obvious extra hepatic metastasis in imaging examination for the first time, it was the recurrence. According to the first time of discovering recurrent lesion, it was divided into early recurrence (≤1 year) and late recurrence (\>1 year).

### Statistical analysis

All statistics were performed using SPSS 19.0 software (SPSS Inc., Chicago, IL, USA). t-test was performed for the comparison of mean value, Chi-square test for the significant difference between groups. Binary logistic regression analysis was used to evaluate the relationship between the parameters of ultrasound contrast and prognostic factors. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Ki-67/AFP immunohistochemistry

In this study, the clinical characteristics between Ki-67 positive group ([Fig. 1](#f1-ol-0-0-7792){ref-type="fig"}) and Ki-67 negative group ([Fig. 1](#f1-ol-0-0-7792){ref-type="fig"}), AFP positive group and AFP negative group were compared. There were no statistically significant differences in the age, sex, positive rate of hepatitis B serum marker and liver function Child-Pugh grade between the two groups (P\>0.05); but the proportion of high-differentiated liver cancer in Ki-67 negative group was higher than that in Ki-67 positive group, and the proportion of low-differentiated liver cancer in Ki-67 positive group was higher than that in Ki-67 negative group (P\<0.05) ([Table I](#tI-ol-0-0-7792){ref-type="table"}).

### Microvessel density (MVD)

In this study, the mean MVD of patients was 63.40, and they were divided into the high-MVD group (greater than the mean) and low-MVD group (lower than the mean) ([Fig. 2](#f2-ol-0-0-7792){ref-type="fig"}). There were no statistically significant differences in the age, sex, hepatitis B serum marker and liver function between high-MVD group and low-MVD group (P\>0.05).

### Microvessel invasion (MVI)

In this study, patients were divided into the MVI-positive group (MVI was found in para-cancer mesenchyme) ([Fig. 3](#f3-ol-0-0-7792){ref-type="fig"}) and MVI-negative group (no MVI was found in para-cancer mesenchyme) ([Fig. 3](#f3-ol-0-0-7792){ref-type="fig"}). There were no statistically significant differences in the age, sex, hepatitis B serum marker and liver function between MVI-positive group and MVI-negative group (P\>0.05).

### Relationship between CEUS parameters vs. pathologic histology

The incidence of positive Ki-67 was high for those cases with obvious change in tumor size, inhomogeneous enhancement and irregular enhancement form of tumor at arterial phase, and low enhancement and fast extinction at portal phase after CEUS (P\<0.05, [Table II](#tII-ol-0-0-7792){ref-type="table"}). There was no significant correlation between the change in tumor size, enhancement mode and form of tumor at arterial phase and other parameters after CEUS and the immunohistochemical AFP (P\>0.05, [Table II](#tII-ol-0-0-7792){ref-type="table"}).

There was no significant correlation between the change in tumor size, enhancement mode and form of tumor at arterial phase and other parameters after CEUS or the MVD level (P\>0.05, [Table III](#tIII-ol-0-0-7792){ref-type="table"}). The incidence of positive MVI was high for those cases with obvious change in tumor size, irregular enhancement form of tumor at arterial phase, tortuous vessels inside and fast extinction at portal phase after CEUS (P\<0.05, [Table III](#tIII-ol-0-0-7792){ref-type="table"}).

The tissue differentiation degree of tumor samples was lower for those cases with inhomogeneous enhancement and irregular enhancement form of tumor at arterial phase, tortuous vessels inside, low enhancement and fast extinction at portal phase after CEUS (P\<0.05, [Table IV](#tIV-ol-0-0-7792){ref-type="table"}).

### CEUS parameters vs. recurrence of liver cancer

The recurrence time was shorter for those cases with inhomogeneous enhancement of tumor at arterial phase in CEUS (P\<0.05, [Table V](#tV-ol-0-0-7792){ref-type="table"} and [Fig. 4](#f4-ol-0-0-7792){ref-type="fig"}).

### Logistic regression for prognostic factors of HCC

Logistic regression showed that the inhomogeneous enhancement inside at the arterial phase in CEUS was more helpful to suggest positive Ki-67 and early recurrence; irregular enhancement form at arterial phase suggested a higher risk of MVI; the low enhancement at portal phase might be a parameter suggesting low tissue differentiation degree (P\<0.05, [Table VI](#tVI-ol-0-0-7792){ref-type="table"}).

Discussion
==========

Approximately 740,000 people die from primary HCC around the world every year, and the patients in China account for more than 50% of the global total ([@b2-ol-0-0-7792]). The high postoperative recurrence rate of liver cancer is the main factor influencing the survival rate of patients with liver cancer. Early prediction of related risk factors to postoperative recurrence of liver cancer is of great clinical significance, and examining the postoperative recurrence as soon as possible and taking treatment measures timely can effectively improve the prognosis of patients with liver cancer ([@b4-ol-0-0-7792]).

The prognosis of HCC patients is determined by a variety of factors. Immunohistochemical Ki-67 is a rapid, simple and sensitive detection technique for proliferative activity of liver cancer cells, and its overexpression (\>10%) can predict the recurrence of liver cancer after surgical treatment, which is associated with the mortality of HCC patients ([@b5-ol-0-0-7792]--[@b7-ol-0-0-7792]). In this study, the change in lesion size, the enhancement mode and form inside lesion at arterial phase, and the enhancement intensity, extinction time and degree at portal phase were associated with the incidence of positive Ki-67; and the logistic regression analysis showed that the inhomogeneous enhancement inside the lesion at arterial phase might be the best parameter to predict the Ki-67 overexpression.

AFP is an important biological marker of liver cancer, whose quantification and immunohistochemistry is associated with the occurrence and development of liver cancer. In recent years, the studies show that AFP lacks sufficient sensitivity and specificity in the effective diagnosis and monitoring of liver cancer. There are few studies about the CEUS parameters and immunohistochemical level of AFP. The results of this study suggested that there was no obvious relationship between the immunohistochemistry AFP and CEUS parameters.

Tumor growth and metastasis depend on the growth of tumor angiogenesis, and MVD, as a sign of tumor angiogenesis degree, also suggests that it is closely related to the occurrence, development and metastasis of tumors ([@b11-ol-0-0-7792],[@b12-ol-0-0-7792]). Compared with liver cancer patients with low MVD, patients with high MVD tend to suffer from early postoperative recurrence. Some scholars studied the correlation between time intensity curve and MVD, and found that the peak intensity, intensity enhancement and area under the curve were positively correlated to the MVD count ([@b13-ol-0-0-7792]), but in this study, the change in tumor size, enhancement form at arterial phase and other parameters after CEUS had no significant relationship with MVD count.

MVI of liver cancer means that the cancer cells have the potential of intrahepatic metastasis and spread to the circulatory system ([@b14-ol-0-0-7792],[@b15-ol-0-0-7792]). In this study, it can be seen that the change in lesion size, enhancement form at arterial phase, tortuous vessels inside and extinction time at portal phase were related to MVI. Logistic regression analysis showed that irregular form at arterial phase was the most closely related to MVI. The irregular enhancement form of lesion at arterial phase is associated with the high incidence of MVI from both univariate and multivariate regression analysis, which may be the most valuable independent factor of predicting MVI.

Typical CEUS of HCC is characterized by high enhancement of lesion at arterial phase and low enhancement at portal phase and delayed phase, namely the so-called 'fast in and fast out' of contrast agent. However, the high-differentiated HCC may present the atypical imaging manifestations, such as the 'fast in and slow out' or 'slow in and slow out' of contrast agent ([@b8-ol-0-0-7792]--[@b10-ol-0-0-7792]). In this study, the enhancement mode and form of lesions at arterial phase, tortuous vessels, and the enhancement intensity, extinction time and degree at portal phase were correlated with the pathological tissue differentiation degree. Logistic regression analysis showed that the inhomogeneous enhancement inside lesions at arterial phase and low enhancement at portal phase were risk factors of low tissue differentiation degree. Compared with the inhomogeneous enhancement at arterial phase, low enhancement at portal phase is more dangerous. The study results showed that the proportion of high or equal enhancement at portal phase in high-differentiated HCC group was significantly higher than that in moderate- and low-differentiated group, and the reason may be that: i) high-differentiated HCC causes the retention of contrast agent due to the presence of neat bone trabecula-type cellular bundles and a large number of hepatic sinusoids; ii) with the increase of malignancy degree, the degree of differentiation becomes lower and the abnormal arteries are formed derived from the increase of abnormal arterial blood supply. Normal blood supply in hepatic artery and portal vein decreases, the duration of enhancement at portal phase declines and the enhancement intensity is lower; iii) there are many abnormal new vessels at the center or around the tumor, as well as abundant arteriovenous fistulas, thus shortening the duration of enhancement.

To sum up, this study investigated the relationship between the enhancement pattern and parameters of CEUS for HCC and the prognostic factors and clinical recurrence, and evaluated the biological behavior and prognosis of liver cancer from the perspective of pathology and ultrasonography, so as to provide a new prognosis evaluation index.

On the background of liver cirrhosis, there were significant differences in different enhancement modes and quantification parameters of contrast-enhancement ultrasound for HCC with different expression of Ki-67. The high incidence of positive Ki-67 may suggest poor prognosis. CEUS is helpful to predict the prognosis of HCC. The inhomogeneous enhancement at arterial phase may predict the proliferative activity and recurrence time of tumor cells; irregular enhancement form at arterial phase may indicate tumor MVI; and the low enhancement of tumor at portal phase may predict a lower degree of tissue differentiation and poor prognosis.
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###### 

Basic characteristics of Ki-67(+)/Ki-67(−) HCC subjects.

  Factors                               Ki-67(+)     Ki-67(−)     Test value   P-value
  ------------------------------------- ------------ ------------ ------------ ---------
  Sex (male %)                          90.01%       91.97%       χ^2^=0.23    0.57
  Age                                   45.90±8.76   48.86±9.34   t=1.74       0.23
  Tumor tissue differentiation degree                             χ^2^=16.28   NS
    High-differentiated                   2.63%      15.57%                    
    Medium-differentiated               81.87%       79.96%                    
    Low-differentiated                  15.50%       4.47%                     
  Hepatitis B serum marker                                        χ^2^=4.26    0.08
    Positive                            99           69                        
    Negative                              6            6                       
  Liver function Child-Pugh grade                                 χ^2^=0.02    0.88
    Grade A                             96           70                        
    Grade B                               9            5                       

HCC, hepatocellular carcinoma; Ki-67(+), Ki-67-positive group; Ki-67(−), Ki-67-negative group. NS, not significant.

###### 

Comparison of CEUS parameters in Ki-67/AFP different HCC groups.

  Factors                                 Ki-67(+)   Ki-67(−)   χ^2^ test   P-value   AFP(+)   AFP(−)   χ^2^ test   P-value
  --------------------------------------- ---------- ---------- ----------- --------- -------- -------- ----------- ---------
  Change of tumor size                                          6.15        0.01                        2.31        0.10
    Conspicuous                           46         20                               40       26                   
    Inconspicuous                         59         55                               54       60                   
  Enhancement mode at arterial phase                            6.57        0.00                        0.13        1.13
    Inhomogeneous                         79         34                               59       55                   
    Homogeneous                           26         41                               35       31                   
  Enhancement form at arterial phase                            7.34        0.02                        0.98        0.56
    Irregular                             49         21                               40       31                   
    Regular                               56         54                               54       55                   
  Tortuous vessels                                              2.39        0.26                        1.13        0.63
    Yes                                   44         24                               33       36                   
    No                                    61         51                               61       50                   
  Enhancement intensity at portal phase                         7.43        0.04                        1.77        0.46
    Low intensity                         81         39                               64       56                   
    High or equal intensity               24         36                               30       30                   
  Extinction speed at portal phase                              8.12        0.05                        3.12        0.50
    Fast                                  55         24                               39       41                   
    Low                                   50         51                               55       45                   
  Extinction extent at portal phase                             8.64        0.04                        0.85        0.67
    Obvious                               79         37                               62       56                   
    None or slight                        26         38                               32       30                   

HCC, hepatocellular carcinoma; Ki-67(+), Ki-67-positive group; Ki-67(−), Ki-67-negative group.

###### 

Comparison of CEUS parameters in MVD/MVI different HCC groups.

  Factors                                 H-MVD   L-MVD   χ^2^ test   P-value   MVI(+)   MVI(−)   χ^2^ test   P-value
  --------------------------------------- ------- ------- ----------- --------- -------- -------- ----------- ---------
  Change of tumor size                                    0.75        0.55                        7.05        0.04
    Conspicuous                           39      32                            56       15                   
    Inconspicuous                         53      56                            74       35                   
  Enhancement mode at arterial phase                      0.34        0.69                        3.50        0.16
    Inhomogeneous                         59      54                            87       26                   
    Homogeneous                           33      34                            43       24                   
  Enhancement form at arterial phase                      0.72        0.45                        5.70        0.01
    Irregular                             41      33                            60       14                   
    Regular                               51      55                            70       36                   
  Tortuous vessels                                        0.13        0.56                        5.70        0.01
    Yes                                   39      35                            60       14                   
    No                                    53      53                            70       36                   
  Enhancement intensity at portal phase                   1.55        0.32                        3.12        0.14
    Low intensity                         65      57                            93       29                   
    High or equal intensity               27      31                            37       21                   
  Extinction speed at portal phase                        2.31        0.42                        3.54        0.03
    Fast                                  40      45                            67       17                   
    Low                                   52      43                            63       33                   
  Extinction extent at portal phase                       1.75        0.33                        3.88        0.14
    Obvious                               65      57                            92       29                   
    None or slight                        27      31                            38       21                   

HCC, hepatocellular carcinoma; CEUS, contrast-enhancement ultrasound; H-MVD, high microvessel density; L-MVD, low microvessel density; MVI(+), microvessel invasion-positive group; MVI(−), microvessel invasion-negative group.

###### 

Comparison of CEUS parameters in tumor tissue differentiation HCC groups.

  Factors                                 Low/Medium-differentiated   Highly-differentiated   χ^2^ test   P-value
  --------------------------------------- --------------------------- ----------------------- ----------- ---------
  Change of tumor size                                                                        4.34        0.07
    Conspicuous                             64                          8                                 
    Inconspicuous                           96                        22                                  
  Enhancement mode at arterial phase                                                          6.75        0.01
    Inhomogeneous                         105                         12                                  
    Homogeneous                             45                        18                                  
  Enhancement form at arterial phase                                                          5.12        0.04
    Irregular                               66                          8                                 
    Regular                                 84                        22                                  
  Tortuous vessels                                                                            7.13        0.03
    Yes                                     64                          7                                 
    No                                      86                        23                                  
  Enhancement intensity at portal phase                                                       6.45        0.01
    Low intensity                         102                         13                                  
    High or equal intensity                 48                        17                                  
  Extinction speed at portal phase                                                            6.83        0.00
    Fast                                  106                         12                                  
    Low                                     44                        18                                  
  Extinction extent at portal phase                                                           4.27        0.04
    Obvious                                 68                          9                                 
    None or slight                          82                        21                                  

HCC, hepatocellular carcinoma; CEUS, contrast-enhancement ultrasound.

###### 

Comparison of CEUS parameters in different recurrence conditions of HCC groups.

  Factors                                 Early recurrence   Late recurrence   No recurrence   χ^2^ test   P-value
  --------------------------------------- ------------------ ----------------- --------------- ----------- ---------
  Change of tumor size                                                                         1.90        0.43
    Conspicuous                           26                   8               38                          
    Inconspicuous                         35                 17                56                          
  Enhancement mode at arterial phase                                                           7.84        0.04
    Inhomogeneous                         40                 10                59                          
    Homogeneous                           21                 15                35                          
  Enhancement form at arterial phase                                                           5.87        0.07
    Irregular                             28                   7               42                          
    Regular                               33                 18                52                          
  Tortuous vessels                                                                             4.30        0.38
    Yes                                   29                   9               35                          
    No                                    32                 16                59                          
  Enhancement intensity at portal phase                                                        4.12        0.30
    Low intensity                         40                 12                61                          
    High or equal intensity               21                 13                33                          
  Extinction speed at portal phase                                                             5.13        0.24
    Fast                                  30                   8               41                          
    Low                                   31                 17                53                          
  Extinction extent at portal phase                                                            3.07        0.36
    Obvious                               40                 12                59                          
    None or slight                        21                 13                35                          

HCC, hepatocellular carcinoma; CEUS, contrast-enhancement ultrasound.

###### 

Logistic regression of HCC prognosis factors.

  Factors                                              r-value   Wald value   P-value   OR
  ---------------------------------------------------- --------- ------------ --------- ------
  Ki-67                                                                                 
    Inhomogeneous enhancement mode at arterial phase   1.15      26.39        NS        2.78
  MVI                                                                                   
    Irregular enhancement form at arterial phase       1.26      17.35        NS        3.10
  Tumor tissue differentiation                                                          
    Inhomogeneous enhancement mode at arterial phase   1.20        7.03       0.02      3.25
    Low intensity enhancement at portal phase          1.55      12.39        NS        4.23

HCC, hepatocellular carcinoma; MVI, microvessel invasion; OR, odds ratio. NS, not significant.
